Page last updated: 2024-08-02 22:20:45
lc15-0444
Description
LC15-0444: Dipeptidyl Peptidase IV Inhibitors; orally active small molecule for the treatment of type II diabetes [MeSH]
gemigliptin : no description available [CHeBI]
Cross-References
Synonyms (33)
| Synonym |
|---|
| CHEBI:134731 |
| gemigliptin |
| lc15-0444 |
| pyrido(3,4-d)pyrimidine, 7-((3s)-3-amino-4-(5,5-difluoro-2-oxo-1-piperidinyl)-1-oxobutyl)-5,6,7,8-tetrahydro-2,4-bis(trifluoromethyl)- |
| 2-piperidinone, 1-((2s)-2-amino-4-(5,8-dihydro-2,4-bis(trifluoromethyl)pyrido(3,4-d)pyrimidin-7(6h)-yl)-4-oxobutyl)-5,5-difluoro- |
| gemigliptin [inn] |
| 5dhu18m5d6 , |
| 911637-19-9 |
| 1-((2s)-2-amino-4-(2,4-bis(trifluoromethyl)-5,8-dihydropyrido(3,4-d)pyrimidin-7(6h)-yl)-4-oxobutyl-5,5-difluoropiperidin-2-one |
| unii-5dhu18m5d6 |
| D10502 |
| gemigliptin (prop.inn) |
| gemigliptin [who-dd] |
| 1-((2s)-2-amino-4-(2,4-bis(trifluoromethyl)-5,8-dihydropyrido(3,4-d)pyrimidin-7(6h)-yl)-4-oxobutyl)-5,5-difluoropiperidin-2-one |
| lc-150444 |
| lc-15-0444 |
| CHEMBL3707235 |
| SCHEMBL1262740 |
| AKOS025290873 |
| (s)-1-(2-amino-4-(2,4-bis(trifluoromethyl)-5,8-dihydropyrido[3,4-d]pyrimidin-7(6h)-yl)-4-oxobutyl)-5,5-difluoropiperidin-2-one |
| (s)-1-(2-amino-4-(2,4-bis(trifluoromethyl)-5,6-dihydropyrido[3,4-d]pyrimidin-7(8h)-yl)-4-oxobutyl)-5,5-difluoropiperidin-2-one , |
| DB12412 |
| A854536 |
| Q5530612 |
| CS-0003618 |
| HY-14892 |
| 1-[(2s)-2-amino-4-[2,4-bis(trifluoromethyl)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-7-yl]-4-oxobutyl]-5,5-difluoropiperidin-2-one |
| 911637-19-9 (free base) |
| gemigliptin hydrochloride |
| AS-75936 |
| DTXSID501030150 |
| zwprrqznbdyklh-vifpvbqesa-n |
| 1-[(2s)-2-amino-4-[2,4-bis(trifluoromethyl)-6,8-dihydro-5h-pyrido[3,4-d]pyrimidin-7-yl]-4-oxo-butyl]-5,5-difluoro-piperidin-2-one |
Drug Classes (2)
Research
Studies (70)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (2.86) | 29.6817 |
| 2010's | 49 (70.00) | 24.3611 |
| 2020's | 19 (27.14) | 2.80 |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 37 (52.86%) | 5.53% |
| Reviews | 3 (4.29%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 1 (1.43%) | 0.25% |
| Other | 29 (41.43%) | 84.16% |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| carbamic acid | | carbon oxoacid;
one-carbon compound;
organonitrogen compound | Escherichia coli metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-carboxyethyl gamma-aminobutyric acid | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| carcinine | | beta-alanine derivative;
imidazoles;
monocarboxylic acid amide;
organonitrogen compound;
organooxygen compound | antioxidant;
crustacean metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nialamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| oxiracetam | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| piracetam | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1,6-bis(cyclohexyloximinocarbonyl)hexane | | carbamate ester;
organonitrogen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| etozolin | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cuprizone | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tetranitromethane | | organonitrogen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| alpha-fluoro-beta-alanine | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-amino-3-phenylbutyric acid | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lodoxamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| Arbaclofen | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pramiracetam | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| azidoamphenicol | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| telmesteine | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pivagabine | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nefiracetam | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| betamipron | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-carboxythiazolidine-4-carboxylic acid | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5,5-dimethylthiazolidine-4-carboxylic acid | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| n-nitrosothiazolidine-4-carboxylic acid | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pyridinoline | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-(isopropylamino)-2-(2-pyridyl)-2-phenylbutyramide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-methyl-5-nitroimidazol-1-ylacetic acid | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-carboxymethyl-6-benzyl-2,5-diketopiperazine | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3,5-diiodothyronine | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| methyl 4-mercaptobutyrimidate | | organonitrogen compound;
oxoacid derivative | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 8-(3-carboxy-1-methylpropylamino)-6-methoxyquinoline | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| merodantoin | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| argininic acid | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| delta-guanidinovaleric acid | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| isoputreanine | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cyclo(glycylprolyl) | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cyclo(tyrosyl-prolyl) | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-cyclopropyl-N-[2-[(4-methoxyphenyl)methylamino]-2-oxo-1-thiophen-2-ylethyl]-4-thiadiazolecarboxamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[2-(cyclopentylamino)-1-(5-methyl-2-furanyl)-2-oxoethyl]-N-[(4-fluorophenyl)methyl]-4-thiadiazolecarboxamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[2-(cyclohexylamino)-1-(2-furanyl)-2-oxoethyl]-N-(2-furanylmethyl)-2-furancarboxamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[[2-(1-benzotriazolyl)-1-oxoethyl]-(thiophen-2-ylmethyl)amino]-2-(2-furanyl)-N-(3-methylbutyl)acetamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-butan-2-yl-N-[2-[(4-methoxyphenyl)methylamino]-2-oxoethyl]-4-thiadiazolecarboxamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N'-[2-(cyclohexylamino)-2-oxoethyl]-N-(5-methyl-3-isoxazolyl)-N'-phenylpentanediamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[2-(5-chloro-2-methoxyanilino)-2-oxoethyl]-N-cyclohexyl-2-furancarboxamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(N-[2-(1-benzotriazolyl)-1-oxoethyl]-4-methoxyanilino)-N-(2-methylbutan-2-yl)-2-(1-methyl-2-pyrrolyl)acetamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(N-[2-(1-benzotriazolyl)-1-oxoethyl]-4-methylanilino)-N-(2-furanylmethyl)-2-(3-pyridinyl)acetamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[2-(tert-butylamino)-2-oxo-1-pyridin-4-ylethyl]-N-cyclopropyl-4-thiadiazolecarboxamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-cyclopentyl-2-[2-oxolanylmethyl-(1-oxo-2-thiophen-2-ylethyl)amino]-2-thiophen-2-ylacetamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N'-[2-(cyclopentylamino)-2-oxo-1-pyridin-4-ylethyl]-N'-(3-fluorophenyl)-N-(3-pyridinyl)butanediamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(2,4-dioxo-3-thiazolidinyl)-N-(2,3,4-trifluorophenyl)acetamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-tert-butyl-2-(2-furanyl)-2-[[2-[5-(5-methyl-2-furanyl)-2-tetrazolyl]-1-oxoethyl]-(thiophen-2-ylmethyl)amino]acetamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N'-[1-[(cyclohexylamino)-oxomethyl]cyclopentyl]-N-(5-methyl-3-isoxazolyl)-N'-phenylbutanediamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[[2-(1-benzotriazolyl)-1-oxoethyl]-propan-2-ylamino]-2-(2,5-dimethoxyphenyl)-N-(2-furanylmethyl)acetamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[[2-(1-benzotriazolyl)-1-oxoethyl]-(2-furanylmethyl)amino]-N-cyclohexyl-2-(2-fluorophenyl)acetamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N'-[2-(cyclopentylamino)-2-oxoethyl]-N'-(3,4-dimethylphenyl)-N-(2-pyridinyl)pentanediamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(1,3-benzodioxol-5-yl)-N-[1-(4-chlorophenyl)-2-(cyclohexylamino)-2-oxoethyl]-2-pyrazinecarboxamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[(3-methyl-2,4-dioxo-5-thiazolidinyl)amino]benzoic acid | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-amino-N5-[2-(2-methoxyethylamino)-1-(5-methyl-2-furanyl)-2-oxoethyl]-N5-(thiophen-2-ylmethyl)isothiazole-3,5-dicarboxamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N'-[2-(cyclopentylamino)-2-oxo-1-pyridin-4-ylethyl]-N-(5-methyl-3-isoxazolyl)-N'-phenylbutanediamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[1,3-benzodioxol-5-yl-[2-(1-benzotriazolyl)-1-oxoethyl]amino]-N-(2-methoxyethyl)-2-thiophen-2-ylacetamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[2-[cyano-(4,6-dimethyl-2-pyrimidinyl)amino]-1-oxoethyl]-4-piperidinecarboxamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-[3-(4-methoxyanilino)-3-oxopropyl]-1-piperazinecarboxylic acid ethyl ester | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-[[(5-bromo-3-pyridinyl)-oxomethyl]amino]propanoic acid | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(2,4-dimethoxyphenyl)-3-(4-morpholinyl)propanamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[[2-(3-methylanilino)-1-oxoethyl]amino]-3-phenylthiourea | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(2,3-dimethyl-1-indolyl)-2-(4-methyl-1-piperidinyl)ethanone | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(N-[2-(Benzotriazol-1-yl)acetyl]-4-methoxyanilino)-N-cyclopentylcyclohexane-1-carboxamide | | organonitrogen compound;
organooxygen compound | anticoronaviral agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-(4-methylphenyl)-2-[[3-(4-morpholinyl)-1-oxopropyl]amino]-3-thiophenecarboxylic acid ethyl ester | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[(4-fluorophenyl)hydrazo]-2-oxoacetic acid ethyl ester | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-[(3,5-dimethylphenyl)-oxomethyl]-1,3-dihydroquinoxalin-2-one | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(3,5-dimethoxyphenyl)-2-(2,2-dimethyl-5-oxo-4-phenyl-1-imidazolyl)acetamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-[(2-chlorophenyl)hydrazo]-3,3-bis(hydroxymethyl)-2H-1,4-oxazin-6-one | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[(3-acetyl-5-oxo-4H-imidazol-2-yl)thio]-N-(4-methyl-5-phenyl-2-thiazolyl)-N-prop-2-enylacetamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[(3-acetyl-5-oxo-4H-imidazol-2-yl)thio]-N-(4,5-diphenyl-2-thiazolyl)acetamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-chloro-N-[3-[(6-methoxy-1,3-benzothiazol-2-yl)amino]-3-oxopropyl]benzamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-bromo-N-[3-oxo-3-(2-thiazolylamino)propyl]benzamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[3-[4-[(2-methoxyphenyl)sulfamoyl]anilino]-3-oxopropyl]-2-furancarboxamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-(4-Chloroanilino)propanoic acid | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1,4-dihydroxy-4a,5,6,7,8,8a-hexahydroquinoxaline-2,3-dione | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(2-furanyl)-4-thiazolidinecarboxylic acid | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| methyl-thiohydantoin-tryptophan | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-hydroxy-7-methyl-3-(4-morpholinyl)-5-nitro-1H-indol-2-one | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-bromo-3-hydroxy-3-(4-methyl-1-piperidinyl)-1H-indol-2-one | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(3,4-dimethylphenyl)-2-(4-methylanilino)-6-oxo-4,5-dihydro-1H-pyrimidine-4-carboxamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(3-chloro-4-methylphenyl)-4-oxo-3,10-dihydro-2H-pyrimido[1,2-a]benzimidazole-2-carboxamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[2-(1-azepanyl)-2-oxoethyl]-N-[(4-chlorophenyl)methyl]methanesulfonamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[1-[[[(3-chloro-1-benzothiophen-2-yl)-oxomethyl]amino]-sulfanylidenemethyl]-3-oxo-2-piperazinyl]acetic acid methyl ester | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(2-methoxy-2-oxoethyl)-3-oxo-1-piperazinecarboxylic acid tert-butyl ester | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| albutoin | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-thioxo-4-thiazolidinecarboxylic acid | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[[2-(4-chlorophenyl)-1,3-dioxo-7,7a-dihydro-3aH-octahydro-1H-4,7-epoxyisoindol-4-yl]methyl]benzenesulfonamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-methyl-2-[3-methyl-4-(3-methylphenyl)azo-5-oxo-4H-pyrazol-1-yl]-5-thiazolecarboxylic acid ethyl ester | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5'-(4-methylphenyl)-2-spiro[1H-indole-3,2'-3H-1,3,4-thiadiazole]one | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[2-(cyclopentylamino)-1-(4-fluorophenyl)-2-oxoethyl]-N-[(4-fluorophenyl)methyl]-1H-pyrazole-5-carboxamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[2-(cyclopentylamino)-1-(3,4-dimethoxyphenyl)-2-oxoethyl]-N-[(4-fluorophenyl)methyl]-1H-pyrazole-5-carboxamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(2-furanyl)-2-[(4-methoxyphenyl)methyl-[2-[5-(5-methyl-2-furanyl)-2-tetrazolyl]-1-oxoethyl]amino]-N-(2-oxolanylmethyl)acetamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[cyclopentyl-[1-oxo-2-(5-thiophen-2-yl-2-tetrazolyl)ethyl]amino]-N-(2-oxolanylmethyl)-2-thiophen-2-ylacetamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(N-[2-(Benzotriazol-1-yl)acetyl]-2,4,6-trimethylanilino)-N-tert-butyl-2-thiophen-3-ylacetamide | | organonitrogen compound;
organooxygen compound | anticoronaviral agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| CID 3206295 | | organonitrogen compound;
organooxygen compound | anticoronaviral agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-tert-butyl-2-[(2-chloro-1-oxoethyl)-(2-furanylmethyl)amino]-2-(4-chlorophenyl)acetamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N'-(1,3-benzodioxol-5-ylmethyl)-N'-[2-(cyclopentylamino)-2-oxoethyl]-N-(5-methyl-3-isoxazolyl)butanediamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[[2-(1-benzotriazolyl)-1-oxoethyl]-(3-pyridinyl)amino]-2-(4-chlorophenyl)-N-(2-methoxyethyl)acetamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-cyclohexyl-2-(4-fluoro-N-[1-oxo-2-(3-thiophenyl)ethyl]anilino)-2-(4-fluorophenyl)acetamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(2-methyl-2,3-dihydroindol-1-yl)-2-[4-[5-(trifluoromethyl)-1-benzotriazolyl]-1-piperidinyl]ethanone | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-bromo-N-[2-(2,3-dihydroindol-1-yl)-2-oxoethyl]-N-methyl-2-thiophenesulfonamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-cyclopentyl-3-[(4-methylphenyl)sulfonylamino]propanamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[(5-bromo-2-thiophenyl)sulfonyl-methylamino]-N-(6-methyl-1,3-benzothiazol-2-yl)acetamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-[(4-methoxyphenyl)sulfonylamino]-N-(phenylmethyl)propanamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(4-methyl-1-oxo-[1]benzothiolo[2,3-d]pyridazin-2-yl)propanoic acid | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-amino-4-(1,3-benzothiazol-2-yl)-N-(3-chloro-2-methylphenyl)-5-phenylimino-2H-thiophene-2-carboxamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N,N-dimethylcarbamodithioic acid (1-acetamido-2,2,2-trichloroethyl) ester | | organonitrogen compound;
organosulfur compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-amino-5-cyano-4-(2-fluorophenyl)-2-sulfanylidene-3,4-dihydro-1H-pyridine-3-carboxamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(5-chloro-2-methoxyphenyl)-2-pyridin-4-yl-4,5-dihydrothiazole-4-carboxamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(N-(2-chloro-1-oxoethyl)-3-methoxyanilino)-N-(2-phenylethyl)-2-thiophen-2-ylacetamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(N-(2-chloro-1-oxoethyl)-4-methoxyanilino)-N-(2-phenylethyl)-2-thiophen-2-ylacetamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| LSM-16912 | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(4-phenylmethoxyphenyl)-3-[4-(phenylmethyl)-1-piperazinyl]propanamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3,6-bis[(1H-indol-3-yl)methyl]piperazine-2,5-dione | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[1-(cyclopentylamino)-2-methyl-1-oxobutan-2-yl]-N-(thiophen-2-ylmethyl)-2-pyridinecarboxamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[1-[(cyclohexylamino)-oxomethyl]cyclohexyl]-N-(2-furanylmethyl)-2-pyridinecarboxamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[1-(cyclohexylamino)-2-methyl-1-oxobutan-2-yl]-N-(2-furanylmethyl)-2-pyridinecarboxamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[6-amino-2,4-dioxo-1-(phenylmethyl)-5-pyrimidinyl]-N-ethyl-2-(2-methyl-2,3-dihydroindol-1-yl)acetamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[1-[(cyclohexylamino)-oxomethyl]cyclohexyl]-N-(thiophen-2-ylmethyl)-2-pyrazinecarboxamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[2-(4-methoxyphenyl)-4-[oxo(1-pyrrolidinyl)methyl]-3-thiazolidinyl]-1-propanone | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(N-(2-chloro-1-oxoethyl)-4-fluoroanilino)-N-cyclohexyl-2-(3-pyridinyl)acetamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(N-(2-chloro-1-oxoethyl)-4-methoxyanilino)-N-cyclohexyl-2-(3-pyridinyl)acetamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(3-chloro-N-(2-chloro-1-oxoethyl)anilino)-N-cyclohexyl-2-(3-pyridinyl)acetamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(2,3-dioxo-1-indolyl)-N-(2-phenylethyl)acetamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[5-(phenylmethyl)-2-thiazolyl]-4,5-dihydro-1H-imidazole-2-carboxamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[[(3-amino-4-carbamoyl-5-cyclohexylimino-2H-thiophen-2-yl)-oxomethyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylic acid methyl ester | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-amino-N2-(2,3-dichlorophenyl)-5-(2-methoxyphenyl)imino-2H-thiophene-2,4-dicarboxamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5'-bromo-2'-spiro[1,2-dihydro-4,1,2-benzoxadiazine-3,3'-1H-indole]one | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(3,4-dimethylphenyl)-4-oxo-3,10-dihydro-2H-pyrimido[1,2-a]benzimidazole-2-carboxamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N,N-diethylcarbamodithioic acid (2,2,2-trichloro-1-formamidoethyl) ester | | organonitrogen compound;
organosulfur compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(5,5-dimethyl-7-oxo-4,6-dihydro-1,3-benzothiazol-2-yl)-2-(2,5-dioxo-1-pyrrolidinyl)acetamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[1-[(cyclohexylamino)-oxomethyl]cyclohexyl]-N-(thiophen-2-ylmethyl)-2-pyridinecarboxamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[2-(4-morpholinyl)-2-oxoethyl]-2-pyrido[2,3-b][1,4]thiazinone | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aurantiamine | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-aminolevulinic acid hexyl ester | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| n,n',n''-triacetylfusarinine c | | iron coordination entity;
organonitrogen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gabalid | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[3-[(1,3-dimethyl-2,6-dioxo-4-pyrimidinyl)methylamino]-3-oxopropyl]-3-methoxybenzamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-chloro-N-[4-[3-(methylthio)anilino]-4-oxobutyl]benzamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[2-(2,6-dichloroanilino)-2-oxoethyl]-N-methyl-4-pyridinecarboxamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[2-(4-chlorophenyl)ethyl]-2-[3-[(2-fluorophenyl)methyl]-2-oxo-1-imidazolidinyl]acetamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[3-[(2-chloro-4-fluorophenyl)methyl]-2-oxo-1,3-diazinan-1-yl]-N-cyclooctylacetamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| seletracetam | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| curacin d | | heterocyclic compound;
organonitrogen compound;
organosulfur compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| elagolix | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| citrinadin a | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| moiramide b | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[(1,3-dioxo-2-phenyl-7,7a-dihydro-3aH-octahydro-1H-4,7-epoxyisoindol-4-yl)methyl]-4-methylbenzenesulfonamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(3-chloro-N-(2-chloro-1-oxoethyl)anilino)-N-cyclohexyl-2-(4-methoxyphenyl)acetamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(4-chloro-N-(2-chloro-1-oxoethyl)anilino)-N-cyclohexyl-2-(4-methoxyphenyl)acetamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[(2-chloro-1-oxoethyl)-(2,2-dimethoxyethyl)amino]-2-(4-chlorophenyl)-N-cyclohexylacetamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(4-fluorophenyl)-3-[[2-(4-methylphenyl)-1,3-dioxo-7,7a-dihydro-3aH-octahydro-1H-4,7-epoxyisoindol-4-yl]methyl]thiourea | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(4-methylphenyl)-3-[[2-(4-methylphenyl)-1,3-dioxo-7,7a-dihydro-3aH-octahydro-1H-4,7-epoxyisoindol-4-yl]methyl]thiourea | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(3-chlorophenyl)-3-[[2-(4-methylphenyl)-1,3-dioxo-7,7a-dihydro-3aH-octahydro-1H-4,7-epoxyisoindol-4-yl]methyl]thiourea | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[[2-(4-methylphenyl)-1,3-dioxo-7,7a-dihydro-3aH-octahydro-1H-4,7-epoxyisoindol-4-yl]methyl]-4-phenyl-1-piperazinecarbothioamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-acetamido-N-[4-(4-methylsulfonylphenyl)-2-thiazolyl]-3-phenyl-N-prop-2-enylpropanamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-[4-[2-(2-fluorophenyl)ethylamino]-3-nitrophenyl]-3-[[2-(1-naphthalenyl)-1-oxoethyl]amino]propanamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[(2-ethoxyphenyl)methyl]-3-[(2-oxo-3H-1,3-benzoxazol-6-yl)sulfonylamino]propanamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| (3S)-3-(2-methylpropyl)-4-oxo-3-phenyldiazetidine-1,2-dicarboxylic acid dimethyl ester | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| (3S)-3-(4-methoxyphenyl)-4-oxo-3-propan-2-yldiazetidine-1,2-dicarboxylic acid dimethyl ester | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| (3S)-4-oxo-3-phenyl-3-propan-2-yldiazetidine-1,2-dicarboxylic acid dimethyl ester | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| (3S)-3-cyclopentyl-4-oxo-3-phenyldiazetidine-1,2-dicarboxylic acid dimethyl ester | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| (3R)-3-(4-chlorophenyl)-4-oxo-3-propan-2-yldiazetidine-1,2-dicarboxylic acid diethyl ester | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gsk 1838705a | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-(4-fluorophenylethylamino)-1-methyl-4-(2-methyl-1h-indol-3-yl)-1h-pyrrole-2,5-dione | | maleimides;
organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[(2S,3S)-2-[[cyclohexylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-2-[[[(4-methoxyanilino)-oxomethyl]-methylamino]methyl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[(2S,3S)-2-[[(4-fluorophenyl)sulfonyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| neosurugatoxin | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-(((3-carboxycyclohexyl)amino)carbonyl)-4-(3-(4-(4-phenoxybutoxy)phenyl)propoxy)benzoic acid | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| putreanine | | carboxylic acid anion;
N-substituted putrescine;
organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| santacruzamate a | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[(2-oxo-3-indolyl)amino]-N-(2-phenylethyl)-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pterine-6-carboxylic acid | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| phosphocreatinine | | organonitrogen compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dimethyl pyrocarbonate | | organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| methoxyamine | | organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-acetyltributylcitrate | | organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| guanidine carboxamide | | organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cdta | | organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ammonium bicarbonate | | organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| zinc carbonate | | organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nicofuranose | | organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| etiracetam | | organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| alpha-lapachone | | organic heterotricyclic compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aurofusarin | | organic heterotricyclic compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 7,9-dimethyl-9aH-quinolizine-1,2,3,4-tetracarboxylic acid tetramethyl ester | | organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| paspaline | | organic heterotricyclic compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| salvinorin a | | organic heterotricyclic compound;
organooxygen compound | metabolite;
oneirogen | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sch 45752 | | organic heterotricyclic compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| chlorocarbonic acid | | organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| byssochlamic acid | | organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mirestrol | | organic heterotricyclic compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| columbin | | organic heterotricyclic compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-oxo-3-benzo[h][1]benzopyrancarboxylic acid ethyl ester | | organic heterotricyclic compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-imino-2-benzo[f][1]benzopyrancarbothioamide | | organic heterotricyclic compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-(3-oxo-2-benzo[f][1]benzopyranyl)-1-phenyl-4-pyrazolecarboxaldehyde | | organic heterotricyclic compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(difluoromethyl)-4-benzo[h][1]benzopyranone | | organic heterotricyclic compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| momilactone b | | organic heterotricyclic compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| uccf-029 | | organic heterotricyclic compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| LSM-1924 | | organic heterotricyclic compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| LSM-22738 | | organic heterotricyclic compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| LSM-26445 | | organic heterotricyclic compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| LSM-1925 | | organic heterotricyclic compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| LSM-25964 | | organic heterotricyclic compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(3-oxo-2-benzo[f][1]benzopyranyl)acetamide | | organic heterotricyclic compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| chicoric acid | | organooxygen compound | geroprotector;
HIV-1 integrase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tremortin a | | organic heterotricyclic compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nu 7026 | | organic heterotricyclic compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| terpendole e | | organic heterotricyclic compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| thallusin | | organic heterotricyclic compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aflatrem | | organic heterotricyclic compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| LSM-1873 | | organic heterotricyclic compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| LSM-1834 | | organic heterotricyclic compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| LSM-1287 | | organic heterotricyclic compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| LSM-1675 | | organic heterotricyclic compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| LSM-1312 | | organic heterotricyclic compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| LSM-1315 | | organic heterotricyclic compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 8-epidiosbulbin e acetate | | organic heterotricyclic compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| conocurvone | | organic heterotricyclic compound;
organooxygen compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| Acute Kidney Failure | 0 | | 2015 | 2017 | 8.0 | low | 1 | 0 | 0 | 0 | 2 | 0 |
| Acute Kidney Injury | 0 | | 2015 | 2017 | 8.0 | low | 1 | 0 | 0 | 0 | 2 | 0 |
| Acute Liver Injury, Drug-Induced | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Albuminuria | 0 | | 2015 | 2017 | 8.0 | low | 1 | 0 | 0 | 0 | 3 | 0 |
| Alloxan Diabetes | 0 | | 2016 | 2021 | 6.3 | low | 0 | 0 | 0 | 0 | 2 | 1 |
| Arteriosclerosis, Coronary | 0 | | 2021 | 2021 | 3.0 | low | 1 | 0 | 0 | 0 | 0 | 1 |
| Benign Neoplasms | 0 | | 2020 | 2020 | 4.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Body Weight | 0 | | 2017 | 2017 | 7.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Cancer of the Thyroid | 0 | | 2017 | 2018 | 6.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| Carcinoma | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Carcinoma, Anaplastic | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cardiac Hypertrophy | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cardiomegaly | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cardiometabolic Syndrome | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cardiovascular Diseases | 0 | | 2016 | 2020 | 6.3 | low | 1 | 0 | 0 | 0 | 3 | 0 |
| Carotid Arteriopathies, Traumatic | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Chemical and Drug Induced Liver Injury | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Chronic Kidney Diseases | 0 | | 2017 | 2018 | 6.5 | low | 1 | 0 | 0 | 0 | 2 | 0 |
| Cirrhosis | 0 | | 2014 | 2019 | 7.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| Cirrhosis, Liver | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Complications of Diabetes Mellitus | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Coronary Artery Disease | 0 | | 2021 | 2021 | 3.0 | low | 1 | 0 | 0 | 0 | 0 | 1 |
| Diabetes Mellitus, Adult-Onset | 0 | | 2010 | 2023 | 5.7 | medium | 24 | 0 | 0 | 1 | 22 | 11 |
| Diabetes Mellitus, Type 2 | 1 | | 2010 | 2023 | 5.7 | medium | 24 | 0 | 0 | 1 | 22 | 11 |
| Diabetic Angiopathies | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Diabetic Cardiomyopathies | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Diabetic Glomerulosclerosis | 0 | | 2015 | 2021 | 6.0 | low | 3 | 0 | 0 | 0 | 4 | 1 |
| Diabetic Nephropathies | 0 | | 2015 | 2021 | 6.0 | low | 3 | 0 | 0 | 0 | 4 | 1 |
| Disease Exacerbation | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Disease Models, Animal | 0 | | 2015 | 2023 | 6.3 | low | 0 | 0 | 0 | 0 | 5 | 2 |
| Dyslipidemia | 0 | | 2019 | 2019 | 5.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Dyslipidemias | 0 | | 2019 | 2019 | 5.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Elevated Cholesterol | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Endotoxemia | 0 | | 2017 | 2017 | 7.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Fasting Hypoglycemia | 0 | | 2017 | 2023 | 4.8 | low | 4 | 0 | 0 | 0 | 3 | 1 |
| Fatty Liver | 0 | | 2015 | 2017 | 8.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Fatty Liver, Nonalcoholic | 0 | | 2022 | 2023 | 1.7 | low | 0 | 0 | 0 | 0 | 0 | 3 |
| Fibrosis | 0 | | 2014 | 2019 | 7.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| Hypercholesterolemia | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Hyperglycemia | 0 | | 2016 | 2018 | 7.0 | low | 2 | 0 | 0 | 0 | 4 | 0 |
| Hyperglycemia, Postprandial | 0 | | 2016 | 2018 | 7.0 | low | 2 | 0 | 0 | 0 | 4 | 0 |
| Hyperlipemia | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Hyperlipidemias | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Hyperplasia | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Hypertrophy | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Hypoglycemia | 0 | | 2017 | 2023 | 4.8 | low | 4 | 0 | 0 | 0 | 3 | 1 |
| Inflammation | 0 | | 2014 | 2022 | 6.2 | low | 0 | 0 | 0 | 0 | 4 | 1 |
| Innate Inflammatory Response | 0 | | 2014 | 2022 | 6.2 | low | 0 | 0 | 0 | 0 | 4 | 1 |
| Insulin Resistance | 0 | | 2015 | 2017 | 7.7 | low | 1 | 0 | 0 | 0 | 3 | 0 |
| Insulin Sensitivity | 0 | | 2015 | 2017 | 7.7 | low | 1 | 0 | 0 | 0 | 3 | 0 |
| Kidney Diseases | 1 | | 2014 | 2017 | 8.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Kidney Failure | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Liver Cirrhosis | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Liver Steatosis | 0 | | 2015 | 2017 | 8.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Metabolic Syndrome | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Neointima | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Neoplasms | 1 | | 2020 | 2020 | 4.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Non-alcoholic Fatty Liver Disease | 0 | | 2022 | 2023 | 1.7 | low | 0 | 0 | 0 | 0 | 0 | 3 |
| Obesity | 0 | | 2023 | 2023 | 1.0 | low | 1 | 0 | 0 | 0 | 0 | 1 |
| Proteinuria | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Pulmonary Arterial Remodeling | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Renal Insufficiency | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Renal Insufficiency, Chronic | 0 | | 2017 | 2018 | 6.5 | low | 1 | 0 | 0 | 0 | 2 | 0 |
| Salivary Gland Diseases | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Thyroid Neoplasms | 0 | | 2017 | 2018 | 6.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| Ureteral Obstruction | 0 | | 2014 | 2019 | 7.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Vascular Calcification | 0 | | 2017 | 2021 | 5.0 | low | 1 | 0 | 0 | 0 | 1 | 1 |
| Ventricular Dysfunction | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Weight Gain | 0 | | 2017 | 2023 | 4.0 | low | 2 | 0 | 0 | 0 | 2 | 1 |
Efficacy, safety and albuminuria-reducing effect of gemigliptin in Korean type 2 diabetes patients with moderate to severe renal impairment: A 12-week, double-blind randomized study (the GUARD Study).Diabetes, obesity & metabolism, , Volume: 19, Issue:4, 2017
The Dose-Dependent Organ-Specific Effects of a Dipeptidyl Peptidase-4 Inhibitor on Cardiovascular Complications in a Model of Type 2 Diabetes.PloS one, , Volume: 11, Issue:3, 2016
Gemigliptin improves renal function and attenuates podocyte injury in mice with diabetic nephropathy.European journal of pharmacology, , Aug-15, Volume: 761, 2015
A prospective cohort study on effects of gemigliptin on cardiovascular outcomes in patients with type 2 diabetes (OPTIMUS study).Scientific reports, , 11-04, Volume: 10, Issue:1, 2020
A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes.Lipids in health and disease, , Apr-13, Volume: 16, Issue:1, 2017
The Dose-Dependent Organ-Specific Effects of a Dipeptidyl Peptidase-4 Inhibitor on Cardiovascular Complications in a Model of Type 2 Diabetes.PloS one, , Volume: 11, Issue:3, 2016
Gemigliptin, a DPP4 inhibitor, ameliorates nonalcoholic steatohepatitis through AMP-activated protein kinase-independent and ULK1-mediated autophagy.Molecular metabolism, , Volume: 78, 2023
Efficacy of Gemigliptin Add-on to Dapagliflozin and Metformin in Type 2 Diabetes Patients: A Randomized, Double-Blind, Placebo-Controlled Study (SOLUTION).Endocrinology and metabolism (Seoul, Korea), , Volume: 38, Issue:3, 2023
Comparison of the effects of gemigliptin versus glimepiride on cardiac function in patients with type 2 diabetes uncontrolled with metformin: The gemi-heart study.Diabetes, obesity & metabolism, , Volume: 25, Issue:8, 2023
Efficacy and safety of enavogliflozin versus dapagliflozin added to metformin plus gemigliptin treatment in patients with type 2 diabetes: A double-blind, randomized, comparator-active study: ENHANCE-D study.Diabetes & metabolism, , Volume: 49, Issue:4, 2023
Effects of Initial Combinations of Gemigliptin Plus Metformin Compared with Glimepiride Plus Metformin on Gut Microbiota and Glucose Regulation in Obese Patients with Type 2 Diabetes: The INTESTINE Study.Nutrients, , Jan-03, Volume: 15, Issue:1, 2023
Pharmacokinetic and pharmacodynamic interaction of DWP16001, a sodium-glucose cotransporter 2 inhibitor, with gemigliptin and metformin in healthy adults.British journal of clinical pharmacology, , Volume: 89, Issue:6, 2023
Gemigliptin exerts protective effects against doxorubicin-induced hepatotoxicity by inhibiting apoptosis via the regulation of fibroblast growth factor 21 expression.Biochemical and biophysical research communications, , 10-20, Volume: 626, 2022
Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis.Endocrinology and metabolism (Seoul, Korea), , Volume: 36, Issue:2, 2021
A Multicentre, Multinational, Open-Label, 52-Week Extension Study of Gemigliptin (LC15-0444) Monotherapy in Patients with Type 2 Diabetes Mellitus.Diabetes & metabolism journal, , Volume: 45, Issue:4, 2021
Effect of Dipeptidyl Peptidase-4 (DPP-4) Inhibition on Biomarkers of Kidney Injury and Vascular Calcification in Diabetic Kidney Disease: A Randomized Controlled Trial.Journal of diabetes research, , Volume: 2021, 2021
Comparison of the effects of gemigliptin and dapagliflozin on glycaemic variability in type 2 diabetes: A randomized, open-label, active-controlled, 12-week study (STABLE II study).Diabetes, obesity & metabolism, , Volume: 22, Issue:2, 2020
Efficacy and safety of gemigliptin as add-on therapy to insulin, with or without metformin, in patients with type 2 diabetes mellitus (ZEUS II study).Diabetes, obesity & metabolism, , Volume: 22, Issue:1, 2020
A prospective cohort study on effects of gemigliptin on cardiovascular outcomes in patients with type 2 diabetes (OPTIMUS study).Scientific reports, , 11-04, Volume: 10, Issue:1, 2020
Efficacy and safety of fixed-dose combination therapy with gemigliptin (50 mg) and rosuvastatin compared with monotherapy in patients with type 2 diabetes and dyslipidaemia (BALANCE): A multicentre, randomized, double-blind, controlled, phase 3 trial.Diabetes, obesity & metabolism, , Volume: 21, Issue:1, 2019
Efficacy and Safety of Gemigliptin in Post-Transplant Patients With Type 2 Diabetes Mellitus.Transplantation proceedings, , Volume: 51, Issue:10, 2019
Pharmacokinetic Equivalence of the High Dose Strength Fixed-Dose Combination Tablet of Gemigliptin/Metformin Sustained Release (SR) and Individual Component Gemigliptin and Metformin XR Tablets in Healthy Subjects.Journal of Korean medical science, , Oct-08, Volume: 33, Issue:41, 2018
Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.Diabetes, obesity & metabolism, , Volume: 20, Issue:2, 2018
A 52-week extension study of switching from gemigliptin vs sitagliptin to gemigliptin only as add-on therapy for patients with type 2 diabetes who are inadequately controlled with metformin alone.Diabetes, obesity & metabolism, , Volume: 20, Issue:6, 2018
Effects of gemigliptin, a dipeptidyl peptidase-4 inhibitor, on lipid metabolism and endotoxemia after a high-fat meal in patients with type 2 diabetes.Diabetes, obesity & metabolism, , Volume: 19, Issue:3, 2017
Efficacy, safety and albuminuria-reducing effect of gemigliptin in Korean type 2 diabetes patients with moderate to severe renal impairment: A 12-week, double-blind randomized study (the GUARD Study).Diabetes, obesity & metabolism, , Volume: 19, Issue:4, 2017
Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-Diabetes, obesity & metabolism, , Volume: 19, Issue:5, 2017
Effect of gemigliptin on glycaemic variability in patients with type 2 diabetes (STABLE study).Diabetes, obesity & metabolism, , Volume: 19, Issue:6, 2017
Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind randomized controlled trial (INICOM study).Diabetes, obesity & metabolism, , Volume: 19, Issue:1, 2017
A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes.Lipids in health and disease, , Apr-13, Volume: 16, Issue:1, 2017
The Dose-Dependent Organ-Specific Effects of a Dipeptidyl Peptidase-4 Inhibitor on Cardiovascular Complications in a Model of Type 2 Diabetes.PloS one, , Volume: 11, Issue:3, 2016
Gemigliptin improves renal function and attenuates podocyte injury in mice with diabetic nephropathy.European journal of pharmacology, , Aug-15, Volume: 761, 2015
Evaluation of the pharmacokinetics of the DPP-4 inhibitor gemigliptin when coadministered with rosuvastatin or irbesartan to healthy subjects.Current medical research and opinion, , Volume: 31, Issue:2, 2015
The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].Expert opinion on drug metabolism & toxicology, , Volume: 10, Issue:6, 2014
Gemigliptin, a novel dipeptidyl peptidase-4 inhibitor, exhibits potent anti-glycation properties in vitro and in vivo.European journal of pharmacology, , Dec-05, Volume: 744, 2014
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.Diabetes, obesity & metabolism, , Volume: 15, Issue:6, 2013
A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes.Diabetes, obesity & metabolism, , Volume: 15, Issue:5, 2013
Gemigliptin, a novel dipeptidyl peptidase 4 inhibitor: first new anti-diabetic drug in the history of Korean pharmaceutical industry.Archives of pharmacal research, , Volume: 36, Issue:10, 2013
A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes.Diabetes, obesity & metabolism, , Volume: 12, Issue:12, 2010
Effect of Dipeptidyl Peptidase-4 (DPP-4) Inhibition on Biomarkers of Kidney Injury and Vascular Calcification in Diabetic Kidney Disease: A Randomized Controlled Trial.Journal of diabetes research, , Volume: 2021, 2021
Gemigliptin Attenuates Renal Fibrosis Through Down-Regulation of the NLRP3 Inflammasome.Diabetes & metabolism journal, , Volume: 43, Issue:6, 2019
Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.Diabetes, obesity & metabolism, , Volume: 20, Issue:2, 2018
Efficacy, safety and albuminuria-reducing effect of gemigliptin in Korean type 2 diabetes patients with moderate to severe renal impairment: A 12-week, double-blind randomized study (the GUARD Study).Diabetes, obesity & metabolism, , Volume: 19, Issue:4, 2017
Gemigliptin improves renal function and attenuates podocyte injury in mice with diabetic nephropathy.European journal of pharmacology, , Aug-15, Volume: 761, 2015
Gemigliptin Attenuates Renal Fibrosis Through Down-Regulation of the NLRP3 Inflammasome.Diabetes & metabolism journal, , Volume: 43, Issue:6, 2019
Gemigliptin ameliorates Western-diet-induced metabolic syndrome in mice.Canadian journal of physiology and pharmacology, , Volume: 95, Issue:2, 2017
Dipeptidyl peptidase IV inhibitor protects against renal interstitial fibrosis in a mouse model of ureteral obstruction.Laboratory investigation; a journal of technical methods and pathology, , Volume: 94, Issue:6, 2014
Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.Diabetes, obesity & metabolism, , Volume: 20, Issue:2, 2018
A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes.Lipids in health and disease, , Apr-13, Volume: 16, Issue:1, 2017
Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-Diabetes, obesity & metabolism, , Volume: 19, Issue:5, 2017
Effects of addition of a dipeptidyl peptidase IV inhibitor to metformin on sirolimus-induced diabetes mellitus.Translational research : the journal of laboratory and clinical medicine, , Volume: 174, 2016
Effects of Initial Combinations of Gemigliptin Plus Metformin Compared with Glimepiride Plus Metformin on Gut Microbiota and Glucose Regulation in Obese Patients with Type 2 Diabetes: The INTESTINE Study.Nutrients, , Jan-03, Volume: 15, Issue:1, 2023
Efficacy and safety of gemigliptin as add-on therapy to insulin, with or without metformin, in patients with type 2 diabetes mellitus (ZEUS II study).Diabetes, obesity & metabolism, , Volume: 22, Issue:1, 2020
Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind randomized controlled trial (INICOM study).Diabetes, obesity & metabolism, , Volume: 19, Issue:1, 2017
Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-Diabetes, obesity & metabolism, , Volume: 19, Issue:5, 2017
Hepatoprotective effects of gemigliptin and empagliflozin in a murine model of diet-induced non-alcoholic fatty liver disease.Biochemical and biophysical research communications, , 01-15, Volume: 588, 2022
Gemigliptin Attenuates Renal Fibrosis Through Down-Regulation of the NLRP3 Inflammasome.Diabetes & metabolism journal, , Volume: 43, Issue:6, 2019
Gemigliptin ameliorates Western-diet-induced metabolic syndrome in mice.Canadian journal of physiology and pharmacology, , Volume: 95, Issue:2, 2017
Ameliorating Effect of Gemigliptin on Renal Injury in Murine Adriamycin-Induced Nephropathy.BioMed research international, , Volume: 2017, 2017
Dipeptidyl petidase-IV inhibitor (gemigliptin) inhibits tunicamycin-induced endoplasmic reticulum stress, apoptosis and inflammation in H9c2 cardiomyocytes.Molecular and cellular endocrinology, , Jul-05, Volume: 392, Issue:1-2, 2014
Effects of gemigliptin, a dipeptidyl peptidase-4 inhibitor, on lipid metabolism and endotoxemia after a high-fat meal in patients with type 2 diabetes.Diabetes, obesity & metabolism, , Volume: 19, Issue:3, 2017
Gemigliptin ameliorates Western-diet-induced metabolic syndrome in mice.Canadian journal of physiology and pharmacology, , Volume: 95, Issue:2, 2017
A dipeptidyl peptidase-IV inhibitor improves hepatic steatosis and insulin resistance by AMPK-dependent and JNK-dependent inhibition of LECT2 expression.Biochemical pharmacology, , Nov-01, Volume: 98, Issue:1, 2015
Gemigliptin, a novel dipeptidyl peptidase-IV inhibitor, exerts a synergistic cytotoxicity with the histone deacetylase inhibitor PXD101 in thyroid carcinoma cells.Journal of endocrinological investigation, , Volume: 41, Issue:6, 2018
Synergistic cytotoxicity of the dipeptidyl peptidase-IV inhibitor gemigliptin with metformin in thyroid carcinoma cells.Endocrine, , Volume: 59, Issue:2, 2018
The dipeptidyl peptidase-IV inhibitor gemigliptin alone or in combination with NVP-AUY922 has a cytotoxic activity in thyroid carcinoma cells.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, , Volume: 39, Issue:10, 2017
Effects of Initial Combinations of Gemigliptin Plus Metformin Compared with Glimepiride Plus Metformin on Gut Microbiota and Glucose Regulation in Obese Patients with Type 2 Diabetes: The INTESTINE Study.Nutrients, , Jan-03, Volume: 15, Issue:1, 2023
Efficacy and safety of gemigliptin as add-on therapy to insulin, with or without metformin, in patients with type 2 diabetes mellitus (ZEUS II study).Diabetes, obesity & metabolism, , Volume: 22, Issue:1, 2020
Gemigliptin ameliorates Western-diet-induced metabolic syndrome in mice.Canadian journal of physiology and pharmacology, , Volume: 95, Issue:2, 2017
Gemigliptin, a DPP4 inhibitor, ameliorates nonalcoholic steatohepatitis through AMP-activated protein kinase-independent and ULK1-mediated autophagy.Molecular metabolism, , Volume: 78, 2023
Gemigliptin Alleviates Succinate-Induced Hepatic Stellate Cell Activation by Ameliorating Mitochondrial Dysfunction.Endocrinology and metabolism (Seoul, Korea), , Volume: 37, Issue:6, 2022
Hepatoprotective effects of gemigliptin and empagliflozin in a murine model of diet-induced non-alcoholic fatty liver disease.Biochemical and biophysical research communications, , 01-15, Volume: 588, 2022
Gemigliptin, a DPP4 inhibitor, ameliorates nonalcoholic steatohepatitis through AMP-activated protein kinase-independent and ULK1-mediated autophagy.Molecular metabolism, , Volume: 78, 2023
Gemigliptin Alleviates Succinate-Induced Hepatic Stellate Cell Activation by Ameliorating Mitochondrial Dysfunction.Endocrinology and metabolism (Seoul, Korea), , Volume: 37, Issue:6, 2022
Hepatoprotective effects of gemigliptin and empagliflozin in a murine model of diet-induced non-alcoholic fatty liver disease.Biochemical and biophysical research communications, , 01-15, Volume: 588, 2022
Gemigliptin suppresses salivary dysfunction in streptozotocin-induced diabetic rats.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, , Volume: 137, 2021
Effects of addition of a dipeptidyl peptidase IV inhibitor to metformin on sirolimus-induced diabetes mellitus.Translational research : the journal of laboratory and clinical medicine, , Volume: 174, 2016
Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo.European journal of pharmacology, , Oct-05, Volume: 788, 2016
Pharmacokinetic and pharmacodynamic interaction of DWP16001, a sodium-glucose cotransporter 2 inhibitor, with gemigliptin and metformin in healthy adults.British journal of clinical pharmacology, , Volume: 89, Issue:6, 2023
Efficacy and safety of enavogliflozin versus dapagliflozin added to metformin plus gemigliptin treatment in patients with type 2 diabetes: A double-blind, randomized, comparator-active study: ENHANCE-D study.Diabetes & metabolism, , Volume: 49, Issue:4, 2023
Comparison of the effects of gemigliptin versus glimepiride on cardiac function in patients with type 2 diabetes uncontrolled with metformin: The gemi-heart study.Diabetes, obesity & metabolism, , Volume: 25, Issue:8, 2023
Efficacy of Gemigliptin Add-on to Dapagliflozin and Metformin in Type 2 Diabetes Patients: A Randomized, Double-Blind, Placebo-Controlled Study (SOLUTION).Endocrinology and metabolism (Seoul, Korea), , Volume: 38, Issue:3, 2023
Effects of Initial Combinations of Gemigliptin Plus Metformin Compared with Glimepiride Plus Metformin on Gut Microbiota and Glucose Regulation in Obese Patients with Type 2 Diabetes: The INTESTINE Study.Nutrients, , Jan-03, Volume: 15, Issue:1, 2023
Gemigliptin, a DPP4 inhibitor, ameliorates nonalcoholic steatohepatitis through AMP-activated protein kinase-independent and ULK1-mediated autophagy.Molecular metabolism, , Volume: 78, 2023
Gemigliptin exerts protective effects against doxorubicin-induced hepatotoxicity by inhibiting apoptosis via the regulation of fibroblast growth factor 21 expression.Biochemical and biophysical research communications, , 10-20, Volume: 626, 2022
Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis.Endocrinology and metabolism (Seoul, Korea), , Volume: 36, Issue:2, 2021
Effect of Dipeptidyl Peptidase-4 (DPP-4) Inhibition on Biomarkers of Kidney Injury and Vascular Calcification in Diabetic Kidney Disease: A Randomized Controlled Trial.Journal of diabetes research, , Volume: 2021, 2021
A Multicentre, Multinational, Open-Label, 52-Week Extension Study of Gemigliptin (LC15-0444) Monotherapy in Patients with Type 2 Diabetes Mellitus.Diabetes & metabolism journal, , Volume: 45, Issue:4, 2021
Efficacy and safety of gemigliptin as add-on therapy to insulin, with or without metformin, in patients with type 2 diabetes mellitus (ZEUS II study).Diabetes, obesity & metabolism, , Volume: 22, Issue:1, 2020
Comparison of the effects of gemigliptin and dapagliflozin on glycaemic variability in type 2 diabetes: A randomized, open-label, active-controlled, 12-week study (STABLE II study).Diabetes, obesity & metabolism, , Volume: 22, Issue:2, 2020
A prospective cohort study on effects of gemigliptin on cardiovascular outcomes in patients with type 2 diabetes (OPTIMUS study).Scientific reports, , 11-04, Volume: 10, Issue:1, 2020
Efficacy and Safety of Gemigliptin in Post-Transplant Patients With Type 2 Diabetes Mellitus.Transplantation proceedings, , Volume: 51, Issue:10, 2019
Efficacy and safety of fixed-dose combination therapy with gemigliptin (50 mg) and rosuvastatin compared with monotherapy in patients with type 2 diabetes and dyslipidaemia (BALANCE): A multicentre, randomized, double-blind, controlled, phase 3 trial.Diabetes, obesity & metabolism, , Volume: 21, Issue:1, 2019
A 52-week extension study of switching from gemigliptin vs sitagliptin to gemigliptin only as add-on therapy for patients with type 2 diabetes who are inadequately controlled with metformin alone.Diabetes, obesity & metabolism, , Volume: 20, Issue:6, 2018
Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.Diabetes, obesity & metabolism, , Volume: 20, Issue:2, 2018
Pharmacokinetic Equivalence of the High Dose Strength Fixed-Dose Combination Tablet of Gemigliptin/Metformin Sustained Release (SR) and Individual Component Gemigliptin and Metformin XR Tablets in Healthy Subjects.Journal of Korean medical science, , Oct-08, Volume: 33, Issue:41, 2018
Effect of gemigliptin on glycaemic variability in patients with type 2 diabetes (STABLE study).Diabetes, obesity & metabolism, , Volume: 19, Issue:6, 2017
Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-Diabetes, obesity & metabolism, , Volume: 19, Issue:5, 2017
A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes.Lipids in health and disease, , Apr-13, Volume: 16, Issue:1, 2017
Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind randomized controlled trial (INICOM study).Diabetes, obesity & metabolism, , Volume: 19, Issue:1, 2017
Effects of gemigliptin, a dipeptidyl peptidase-4 inhibitor, on lipid metabolism and endotoxemia after a high-fat meal in patients with type 2 diabetes.Diabetes, obesity & metabolism, , Volume: 19, Issue:3, 2017
Efficacy, safety and albuminuria-reducing effect of gemigliptin in Korean type 2 diabetes patients with moderate to severe renal impairment: A 12-week, double-blind randomized study (the GUARD Study).Diabetes, obesity & metabolism, , Volume: 19, Issue:4, 2017
The Dose-Dependent Organ-Specific Effects of a Dipeptidyl Peptidase-4 Inhibitor on Cardiovascular Complications in a Model of Type 2 Diabetes.PloS one, , Volume: 11, Issue:3, 2016
Gemigliptin improves renal function and attenuates podocyte injury in mice with diabetic nephropathy.European journal of pharmacology, , Aug-15, Volume: 761, 2015
Evaluation of the pharmacokinetics of the DPP-4 inhibitor gemigliptin when coadministered with rosuvastatin or irbesartan to healthy subjects.Current medical research and opinion, , Volume: 31, Issue:2, 2015
The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].Expert opinion on drug metabolism & toxicology, , Volume: 10, Issue:6, 2014
Gemigliptin, a novel dipeptidyl peptidase-4 inhibitor, exhibits potent anti-glycation properties in vitro and in vivo.European journal of pharmacology, , Dec-05, Volume: 744, 2014
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.Diabetes, obesity & metabolism, , Volume: 15, Issue:6, 2013
A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes.Diabetes, obesity & metabolism, , Volume: 15, Issue:5, 2013
Gemigliptin, a novel dipeptidyl peptidase 4 inhibitor: first new anti-diabetic drug in the history of Korean pharmaceutical industry.Archives of pharmacal research, , Volume: 36, Issue:10, 2013
A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes.Diabetes, obesity & metabolism, , Volume: 12, Issue:12, 2010
Effect of Dipeptidyl Peptidase-4 (DPP-4) Inhibition on Biomarkers of Kidney Injury and Vascular Calcification in Diabetic Kidney Disease: A Randomized Controlled Trial.Journal of diabetes research, , Volume: 2021, 2021
Gemigliptin Attenuates Renal Fibrosis Through Down-Regulation of the NLRP3 Inflammasome.Diabetes & metabolism journal, , Volume: 43, Issue:6, 2019
Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.Diabetes, obesity & metabolism, , Volume: 20, Issue:2, 2018
Efficacy, safety and albuminuria-reducing effect of gemigliptin in Korean type 2 diabetes patients with moderate to severe renal impairment: A 12-week, double-blind randomized study (the GUARD Study).Diabetes, obesity & metabolism, , Volume: 19, Issue:4, 2017
Gemigliptin improves renal function and attenuates podocyte injury in mice with diabetic nephropathy.European journal of pharmacology, , Aug-15, Volume: 761, 2015
Gemigliptin, a DPP4 inhibitor, ameliorates nonalcoholic steatohepatitis through AMP-activated protein kinase-independent and ULK1-mediated autophagy.Molecular metabolism, , Volume: 78, 2023
Hepatoprotective effects of gemigliptin and empagliflozin in a murine model of diet-induced non-alcoholic fatty liver disease.Biochemical and biophysical research communications, , 01-15, Volume: 588, 2022
Ameliorating Effect of Gemigliptin on Renal Injury in Murine Adriamycin-Induced Nephropathy.BioMed research international, , Volume: 2017, 2017
The Dose-Dependent Organ-Specific Effects of a Dipeptidyl Peptidase-4 Inhibitor on Cardiovascular Complications in a Model of Type 2 Diabetes.PloS one, , Volume: 11, Issue:3, 2016
Effects of addition of a dipeptidyl peptidase IV inhibitor to metformin on sirolimus-induced diabetes mellitus.Translational research : the journal of laboratory and clinical medicine, , Volume: 174, 2016
Gemigliptin improves renal function and attenuates podocyte injury in mice with diabetic nephropathy.European journal of pharmacology, , Aug-15, Volume: 761, 2015
Dipeptidyl peptidase-4 inhibition by gemigliptin prevents abnormal vascular remodeling via NF-E2-related factor 2 activation.Vascular pharmacology, , Volume: 73, 2015
Gemigliptin Attenuates Renal Fibrosis Through Down-Regulation of the NLRP3 Inflammasome.Diabetes & metabolism journal, , Volume: 43, Issue:6, 2019
Gemigliptin ameliorates Western-diet-induced metabolic syndrome in mice.Canadian journal of physiology and pharmacology, , Volume: 95, Issue:2, 2017
Dipeptidyl peptidase IV inhibitor protects against renal interstitial fibrosis in a mouse model of ureteral obstruction.Laboratory investigation; a journal of technical methods and pathology, , Volume: 94, Issue:6, 2014
Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.Diabetes, obesity & metabolism, , Volume: 20, Issue:2, 2018
A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes.Lipids in health and disease, , Apr-13, Volume: 16, Issue:1, 2017
Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-Diabetes, obesity & metabolism, , Volume: 19, Issue:5, 2017
Effects of addition of a dipeptidyl peptidase IV inhibitor to metformin on sirolimus-induced diabetes mellitus.Translational research : the journal of laboratory and clinical medicine, , Volume: 174, 2016
Effects of Initial Combinations of Gemigliptin Plus Metformin Compared with Glimepiride Plus Metformin on Gut Microbiota and Glucose Regulation in Obese Patients with Type 2 Diabetes: The INTESTINE Study.Nutrients, , Jan-03, Volume: 15, Issue:1, 2023
Efficacy and safety of gemigliptin as add-on therapy to insulin, with or without metformin, in patients with type 2 diabetes mellitus (ZEUS II study).Diabetes, obesity & metabolism, , Volume: 22, Issue:1, 2020
Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-Diabetes, obesity & metabolism, , Volume: 19, Issue:5, 2017
Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind randomized controlled trial (INICOM study).Diabetes, obesity & metabolism, , Volume: 19, Issue:1, 2017
Hepatoprotective effects of gemigliptin and empagliflozin in a murine model of diet-induced non-alcoholic fatty liver disease.Biochemical and biophysical research communications, , 01-15, Volume: 588, 2022
Gemigliptin Attenuates Renal Fibrosis Through Down-Regulation of the NLRP3 Inflammasome.Diabetes & metabolism journal, , Volume: 43, Issue:6, 2019
Ameliorating Effect of Gemigliptin on Renal Injury in Murine Adriamycin-Induced Nephropathy.BioMed research international, , Volume: 2017, 2017
Gemigliptin ameliorates Western-diet-induced metabolic syndrome in mice.Canadian journal of physiology and pharmacology, , Volume: 95, Issue:2, 2017
Dipeptidyl petidase-IV inhibitor (gemigliptin) inhibits tunicamycin-induced endoplasmic reticulum stress, apoptosis and inflammation in H9c2 cardiomyocytes.Molecular and cellular endocrinology, , Jul-05, Volume: 392, Issue:1-2, 2014
Effects of gemigliptin, a dipeptidyl peptidase-4 inhibitor, on lipid metabolism and endotoxemia after a high-fat meal in patients with type 2 diabetes.Diabetes, obesity & metabolism, , Volume: 19, Issue:3, 2017
Gemigliptin ameliorates Western-diet-induced metabolic syndrome in mice.Canadian journal of physiology and pharmacology, , Volume: 95, Issue:2, 2017
A dipeptidyl peptidase-IV inhibitor improves hepatic steatosis and insulin resistance by AMPK-dependent and JNK-dependent inhibition of LECT2 expression.Biochemical pharmacology, , Nov-01, Volume: 98, Issue:1, 2015
Gemigliptin, a novel dipeptidyl peptidase-IV inhibitor, exerts a synergistic cytotoxicity with the histone deacetylase inhibitor PXD101 in thyroid carcinoma cells.Journal of endocrinological investigation, , Volume: 41, Issue:6, 2018
Synergistic cytotoxicity of the dipeptidyl peptidase-IV inhibitor gemigliptin with metformin in thyroid carcinoma cells.Endocrine, , Volume: 59, Issue:2, 2018
The dipeptidyl peptidase-IV inhibitor gemigliptin alone or in combination with NVP-AUY922 has a cytotoxic activity in thyroid carcinoma cells.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, , Volume: 39, Issue:10, 2017
Safety/Toxicity (18)
| Article | Year |
|---|
Efficacy and safety of enavogliflozin versus dapagliflozin added to metformin plus gemigliptin treatment in patients with type 2 diabetes: A double-blind, randomized, comparator-active study: ENHANCE-D study.
Diabetes & metabolism, , Volume: 49, Issue:4 | 2023 |
Gemigliptin exerts protective effects against doxorubicin-induced hepatotoxicity by inhibiting apoptosis via the regulation of fibroblast growth factor 21 expression.
Biochemical and biophysical research communications, , 10-20, Volume: 626 | 2022 |
Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis.
Endocrinology and metabolism (Seoul, Korea), , Volume: 36, Issue:2 | 2021 |
A Fixed-Dose Combination Of Gemigliptin And Rosuvastatin Exhibits Similar Pharmacokinetics, Pharmacodynamics, And Safety Compared To That Of A Loose Combination In Healthy Subjects.
Drug design, development and therapy, , Volume: 13 | 2019 |
Efficacy and Safety of Gemigliptin in Post-Transplant Patients With Type 2 Diabetes Mellitus.
Transplantation proceedings, , Volume: 51, Issue:10 | 2019 |
Efficacy and safety of gemigliptin as add-on therapy to insulin, with or without metformin, in patients with type 2 diabetes mellitus (ZEUS II study).
Diabetes, obesity & metabolism, , Volume: 22, Issue:1 | 2020 |
Efficacy and safety of fixed-dose combination therapy with gemigliptin (50 mg) and rosuvastatin compared with monotherapy in patients with type 2 diabetes and dyslipidaemia (BALANCE): A multicentre, randomized, double-blind, controlled, phase 3 trial.
Diabetes, obesity & metabolism, , Volume: 21, Issue:1 | 2019 |
Protective Effects of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, against Cisplatin-Induced Nephrotoxicity in Mice.
Mediators of inflammation, , Volume: 2017 | 2017 |
Synergistic cytotoxicity of the dipeptidyl peptidase-IV inhibitor gemigliptin with metformin in thyroid carcinoma cells.
Endocrine, , Volume: 59, Issue:2 | 2018 |
Gemigliptin, a novel dipeptidyl peptidase-IV inhibitor, exerts a synergistic cytotoxicity with the histone deacetylase inhibitor PXD101 in thyroid carcinoma cells.
Journal of endocrinological investigation, , Volume: 41, Issue:6 | 2018 |
Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.
Diabetes, obesity & metabolism, , Volume: 20, Issue:2 | 2018 |
Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-
Diabetes, obesity & metabolism, , Volume: 19, Issue:5 | 2017 |
Efficacy, safety and albuminuria-reducing effect of gemigliptin in Korean type 2 diabetes patients with moderate to severe renal impairment: A 12-week, double-blind randomized study (the GUARD Study).
Diabetes, obesity & metabolism, , Volume: 19, Issue:4 | 2017 |
Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind randomized controlled trial (INICOM study).
Diabetes, obesity & metabolism, , Volume: 19, Issue:1 | 2017 |
The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].
Expert opinion on drug metabolism & toxicology, , Volume: 10, Issue:6 | 2014 |
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
Diabetes, obesity & metabolism, , Volume: 15, Issue:6 | 2013 |
A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes.
Diabetes, obesity & metabolism, , Volume: 15, Issue:5 | 2013 |
A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes.
Diabetes, obesity & metabolism, , Volume: 12, Issue:12 | 2010 |
Long-term Use (1)
Pharmacokinetics (17)
| Article | Year |
|---|
Pharmacokinetic and pharmacodynamic interaction of DWP16001, a sodium-glucose cotransporter 2 inhibitor, with gemigliptin and metformin in healthy adults.
British journal of clinical pharmacology, , Volume: 89, Issue:6 | 2023 |
Pharmacokinetic and Pharmacodynamic Comparison of Two Formulations of a Fixed-Dose Combination of Gemigliptin/Rosuvastatin 50/20 mg: A Randomized, Open-Label, Single-Dose, Two-Way Crossover Study.
Drug design, development and therapy, , Volume: 15 | 2021 |
A Fixed-Dose Combination Of Gemigliptin And Rosuvastatin Exhibits Similar Pharmacokinetics, Pharmacodynamics, And Safety Compared To That Of A Loose Combination In Healthy Subjects.
Drug design, development and therapy, , Volume: 13 | 2019 |
Pharmacokinetic comparison of gemigliptin 50 mg and metformin 500 mg as a fixed-dose combination and loose combination
.
International journal of clinical pharmacology and therapeutics, , Volume: 57, Issue:2 | 2019 |
Pharmacokinetic Equivalence of the High Dose Strength Fixed-Dose Combination Tablet of Gemigliptin/Metformin Sustained Release (SR) and Individual Component Gemigliptin and Metformin XR Tablets in Healthy Subjects.
Journal of Korean medical science, , Oct-08, Volume: 33, Issue:41 | 2018 |
Pharmacokinetic Interactions Between Gemigliptin and Metformin, and Potential Differences in the Pharmacokinetic Profile of Gemigliptin Between the Mexican and Korean Populations: A Randomized, Open-label Study in Healthy Mexican Volunteers.
Clinical therapeutics, , Volume: 40, Issue:10 | 2018 |
A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects.
Drug design, development and therapy, , Volume: 9 | 2015 |
Evaluation of the pharmacokinetics of the DPP-4 inhibitor gemigliptin when coadministered with rosuvastatin or irbesartan to healthy subjects.
Current medical research and opinion, , Volume: 31, Issue:2 | 2015 |
Evaluation of pharmacokinetic drug interactions between gemigliptin (dipeptidylpeptidase-4 inhibitor) and glimepiride (sulfonylurea) in healthy volunteers.
Drugs in R&D, , Volume: 14, Issue:3 | 2014 |
The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].
Expert opinion on drug metabolism & toxicology, , Volume: 10, Issue:6 | 2014 |
Effect of renal impairment and haemodialysis on the pharmacokinetics of gemigliptin (LC15-0444).
Diabetes, obesity & metabolism, , Volume: 16, Issue:10 | 2014 |
Pharmacokinetic and pharmacodynamic interaction between gemigliptin and metformin in healthy subjects.
Clinical drug investigation, , Volume: 34, Issue:6 | 2014 |
Effects of food on the pharmacokinetics of gemigliptin/metformin sustained-release 50/1,000 mg (25/500 mg x 2 tablets) fixeddose combination tablet in healthy male volunteers.
International journal of clinical pharmacology and therapeutics, , Volume: 52, Issue:5 | 2014 |
Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: a crossover drug-drug interaction study in healthy male Korean volunteers.
Clinical therapeutics, , Volume: 34, Issue:5 | 2012 |
Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase IV inhibitor LC15-0444 and pioglitazone in healthy volunteers.
International journal of clinical pharmacology and therapeutics, , Volume: 50, Issue:1 | 2012 |
Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers.
British journal of clinical pharmacology, , Volume: 68, Issue:6 | 2009 |
Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
Clinical therapeutics, , Volume: 30, Issue:10 | 2008 |
Bioavailability (1)
Dosage (13)
| Article | Year |
|---|
Pharmacokinetic and Pharmacodynamic Comparison of Two Formulations of a Fixed-Dose Combination of Gemigliptin/Rosuvastatin 50/20 mg: A Randomized, Open-Label, Single-Dose, Two-Way Crossover Study.
Drug design, development and therapy, , Volume: 15 | 2021 |
A Fixed-Dose Combination Of Gemigliptin And Rosuvastatin Exhibits Similar Pharmacokinetics, Pharmacodynamics, And Safety Compared To That Of A Loose Combination In Healthy Subjects.
Drug design, development and therapy, , Volume: 13 | 2019 |
Efficacy and Safety of Gemigliptin in Post-Transplant Patients With Type 2 Diabetes Mellitus.
Transplantation proceedings, , Volume: 51, Issue:10 | 2019 |
Evaluation of the pharmacokinetics of the DPP-4 inhibitor gemigliptin when coadministered with rosuvastatin or irbesartan to healthy subjects.
Current medical research and opinion, , Volume: 31, Issue:2 | 2015 |
Evaluation of pharmacokinetic drug interactions between gemigliptin (dipeptidylpeptidase-4 inhibitor) and glimepiride (sulfonylurea) in healthy volunteers.
Drugs in R&D, , Volume: 14, Issue:3 | 2014 |
Pharmacokinetic and pharmacodynamic interaction between gemigliptin and metformin in healthy subjects.
Clinical drug investigation, , Volume: 34, Issue:6 | 2014 |
Effects of food on the pharmacokinetics of gemigliptin/metformin sustained-release 50/1,000 mg (25/500 mg x 2 tablets) fixeddose combination tablet in healthy male volunteers.
International journal of clinical pharmacology and therapeutics, , Volume: 52, Issue:5 | 2014 |
Gemigliptin, a novel dipeptidyl peptidase 4 inhibitor: first new anti-diabetic drug in the history of Korean pharmaceutical industry.
Archives of pharmacal research, , Volume: 36, Issue:10 | 2013 |
Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: a crossover drug-drug interaction study in healthy male Korean volunteers.
Clinical therapeutics, , Volume: 34, Issue:5 | 2012 |
Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase IV inhibitor LC15-0444 and pioglitazone in healthy volunteers.
International journal of clinical pharmacology and therapeutics, , Volume: 50, Issue:1 | 2012 |
A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes.
Diabetes, obesity & metabolism, , Volume: 12, Issue:12 | 2010 |
Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers.
British journal of clinical pharmacology, , Volume: 68, Issue:6 | 2009 |
Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
Clinical therapeutics, , Volume: 30, Issue:10 | 2008 |
Interactions (3)
| Article | Year |
|---|
The dipeptidyl peptidase-IV inhibitor gemigliptin alone or in combination with NVP-AUY922 has a cytotoxic activity in thyroid carcinoma cells.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, , Volume: 39, Issue:10 | 2017 |
Evaluation of pharmacokinetic drug interactions between gemigliptin (dipeptidylpeptidase-4 inhibitor) and glimepiride (sulfonylurea) in healthy volunteers.
Drugs in R&D, , Volume: 14, Issue:3 | 2014 |
Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: a crossover drug-drug interaction study in healthy male Korean volunteers.
Clinical therapeutics, , Volume: 34, Issue:5 | 2012 |